UNDERSTANDING CANCER AND IMMUNITY: A FRONT-LINE SCIENCE BASED COURSE FOR ALL HEALTH PRACTITIONERS.

An introduction to pathogenetic, pharmacogenetic and immunopathological considerations with respect to development and treatment of cancer and other diseases.

This course has been developed by the cancer specialist, immunologist and molecular pathologist Dr. Peter H Kayto enable all health practitioners to inform cancer patients more about the pros and cons of various treatment options. importantly, it also indicates how AYUSH and other CAM therapies can be integrated most effectively into a truly holistic anti-cancer treatment regime.

Chemotherapy and radiotherapy remain frontline treatments for cancer patients. However, many chemotherapeutic drugs are administered in an inactive form, as a pro-drug. When pro-drugs are absorbed into the bloodstream they need to be activated by an enzyme before they can be of help to the patient. Unfortunately, chemotherapy drugs can be quite dangerous to patients who have inherited an enzyme that activates a pro-drug either too quickly or too slowly. This course includes information about how a genetic typing service can be used to determine whether the patient has inherited a beneficial or harmful genetic type of drug activating enzyme.

Another important consideration with regard to determining the effectiveness of chemotherapy or radiotherapy depends on the genetic status of a gene called TP53. Neoplastic cells in about half of all cancer patients have been foundto have developed a mutant form of the TP53 gene. Recent studies have shown that the presence of a mutant form of TPS3 significantly reduces the benefits of chemotherapy and radiotherapy. TP53 genetics are discussed in detail in the course.

The course also includes a comprehensive introduction to immunity because many aspects of immunity are relevant to the treatment of cancer.

In recent times, cancer cell specific metabolic pathways have been identified. This course also introduces participants to these findings and informs them of ways in which these findings can be used to provide further help to the patient.

Finally, the course introduces participants to a range of RNA based ultra-dilute remedies, based on Patented technology. These new RNA based remedies can be used to support the use of conventional treatments and provide a further treatment option, especially when the use of conventional treatments is contra-indicated.

How to participate.

The course is undertaken completely online. There are no time limits or previous requirements.

The course is divided into five SECTIONS. Participants will receive SECTION I first. At the end of SECTION I, there is a series of IO multiple choice questions. Participants must answer these questions and email their answers to Dr. Peter H Kay at peterhkay@gmail.com On receipt of satisfactory answers, participants will receive SECTION 2. Participants will then send their answers to SECTION 2 multiple choice questions again to Dr. Kay and so on. On completion of all five SECTIONS of the course, participants will be issued with a certificate of completion from the SSB Universal Integrated Medical Health Care Services, India which has been signed by Dr. Peter H Kay.

The cost of the course is 10,000 INR for participants from India, Sri Lanka, Bangladesh, Nepal and Pakistan and 250 USD for participants from other countries.

Course contents

SECTIONS I and 2 deal mainly with oncological considerations and SECTIONS 2 and 3 deal mainly with immunological considerations. SECTION 5 introduces the participant to a series of RNA based ultra-diluted remedies developed to enhance the effects of conventional therapies and help the patient when conventional treatments are contra-indicated.

CONTENTS of SECTION 1

1. Summary of cancer causation.
   This includes introduction to many of the body's defense and repair mechanisms that are relevant to cancer causation and treatment.
2. Factors affecting chemotherapy.
   Different kinds of drugs. Factors affecting their efficacy, genetics and importance of cytochrome P450 enzymes, CYP2D6 and CYP3A4, blood factors, genetic considerations, pharmacogenetics. The significance of multi-drug resistance. Cancer stem cells.





3. What can be done to help chemotherapy and radiotherapy work as effectively as possible.

4. Radiotherapy, pros and cons.
How radiotherapy works, Genetic considerations, radiogenomics, Difficulties with radiotherapy. DNA repair systems. Low dose radiation, benefits.

5. Introduction to immunological aspects.
Immunological factors. Drug / Immune reactions. Monoclonal antibodies, Stem cell transplantation, graft versus host considerations. Dendritic cell therapy.

CONTENTS of SECTION 2

1. Introduction to photodynamic therapy.

2. Understanding spontaneous remission. Oncolytic viral therapy. Infectious anti-cancer agents, Coley's toxins.

3. Cancer cell specific metabolic pathways. How they can be used to develop alternative approaches to cancer treatments.

4. Directions to determine the genetic types of important enzymes.
1s chemotherapy going to be helpful or harmful? Who to contract for genetic typing of genes that encode CY2D6, CYP3A4. and DPYD.

6. Supplementation and dietary considerations.

IMMUNOLOGICAL CONSIDERATIONS.

The contents of sections 3 and 4 introduce participants to various ways in which immune mechanisms can be used to help resolve the development and spread of cancer. It also explains ways in which Immune mechanisms may influence development and resolution of many other diseases that may have the potential to promote neoplastic transformation.

Many substances, remedies or supplements are claimed to "boost" immunity. However, from a health care standpoint, it is important to understand that the immune system comprises many components and that "boosting" or enhancing the activity of some of them can cause the development of many diseases or make some diseases worse. This part of the course has been developed to enable participants to understand more about all the different components of the immune system and how they support health or cause disease.

In this part of the course, participants will also lean how a perfectly normal mother's Immune system can kill her unborn child, why boosting of some parts of the Immune system can cause the development of allergy based diseases such as asthma, how some parts of the Immune system can cause disease by mimicking the uncontrolled action of a hormone, how a healthy transplanted organ can kill the recipient, how the AIDS virus causes immune deficiency and much more.

CONTENTS of SECTION 3

1. Adaptive Immune systems.

2. T cell immunity, T cell functions, B cell immunity. Antibodies, how they are produced. See also reference to monoclonal antibodies in Section I.

3. Generation of diversity. How different substances are recognised by the immune system.

4. IgE and allergy.

CONTENTS of SECTION 4

1. Innate immune systems.
The complement system. Inflammatory cytokines. Natural killer cells. The defensin system. Mannose binding leetin. Bacteriophages.

2. The major histocompatibility complex (MHC).
HLA antigen system. The role of MHC in transplantation. Graft versus host disease. Auto-immune diseases. Detection of auto-immune diseases.

3. Red cell serology.

4. Diseases caused by red cell antibodies, haemolytic disease of the newborn.
Introduction to a newly discovered non-inflammatory form of asthma.






CONTENTS of SECTION 5

Homeogenomic considerations

1. Introduction to Homeogenomics, including history of gene targeting.
2. Development of a RNA based system for reducing gene expression.
3. Introduction to critical genes whose expression is elevated in cancer.
4. Introduction to the range of remedies developed to supress the activity of genes that promote cancer.
5. Introduction to the range of remedies developed to help conventional anti-cancer treatments work better.

Online Contact Proqrams :

Online contact programs will be arranged as and when needed.

Details for the payment of Course Fee:

Payments can be accepted by Cheque or DD or net banking transfer or online payment. Cheques / DDs should be in favour of SSB Universal Integrated Medical Health Care Services Pvt. Ltd., Gudivada.

Bank Account Details :

Account name: SSB Univeral Integrated Medical Health Care Services Pvt.
Ltd.,Account No 1418135000004119
Name of Bank Karur Vysya Bank
LimitedName of Branch Gudivada
IFSC Code KVBL0001418

Brief sketch of Dr. Peter H. Kay

He was the Founder, and for many years, Head of the Molecular Pathology Laboratory in the Dept. of Pathology at the University of Western Australia. During that time, he carried out teaching and research in the fields of cancer, immunopathology and immunogenetics at pre- and post-graduate levels. During his scientific career, he published over 80 papers involving cancer and immunopathological matters.

On this return to the U.K. a few years ago, he began to be asked many questions regarding development and treatment of cancer (and many other conditions) by patients, practitioners and students of the biological sciences. As a consequence, he established a clinic that provides information and support for cancer patients to help them understand the pros and cons of various treatments available to them. To enable others to offer the same information service to cancer patients, he has prepared this science based course that teaches patients as well as practitioners and students of medicine and science] important critical factors that need to be applied to help patients choose the most appropriate treatment on a personal level.

Brief sketch of Dr. Raveendar Chinta.

He was the Former Scientist (AD), Central Council for Research in Homoeopathy, Ministry ofAYUSH, Govt. Of India. He is qualified in Post Graduates of Homoeopathy, Microbiology, Zoology, Psychology, Sociology, Alternative Medicines, Bio-Informatics, Nutrition & Dietetics, Preventive & Promotive Health Care and Holistic Health Care.

He was associated with many Clinical & Fundamental Basic Research Projects of CCRH, Collaborated with many reputed Institutes of Medical & Aliied Sciences in India. Presented 95 Scientific Papers at various International & National Conferences. Resource person for many CME programmes & ROTPs of Min. of AYUSH, Govt. of India. Recipient of WHO Fellowship on Immunocytochemistry & 35 National & International Awards.

Co-author for the books of Homoeopathic Pharmacology & Key note Materia Medica published by CCRH, New Delhi. Member of many important Committees. Nodal Officer for many public health projects, ÏNPCDCS - AYUSH project of MoHFW & Min. of AYUSH, Govt. of India.

WHO CAN JOIN THE COURSE

All the Medical & Health Practitioners of Allopathy, AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy). CAM (Complementary & Alternative Medicine). Physiotherapy, Scientists of Allied Sciences interested in Cancer research, Researchers of Cancer, all the P.G. & U.G. Medical Students of Allopathy & AYUSH / CAM System s, Paramedical Health Peronel and interested Cancer information learning Patients & Persons.